Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Gains from Investment Securities (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Gains from Investment Securities for 11 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 2197.0% to $4.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.3 million, a 110.01% increase, with the full-year FY2025 number at $4.0 million, up 206.31% from a year prior.
  • Gains from Investment Securities was $4.6 million for Q4 2025 at Madrigal Pharmaceuticals, up from $330000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.6 million in Q4 2025 to a low of $200000.0 in Q4 2024.
  • A 3-year average of $1.6 million and a median of $1.2 million in 2024 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 2197.0% in 2025; the steepest drop was 71.75% in 2025.
  • Madrigal Pharmaceuticals' Gains from Investment Securities stood at $1.6 million in 2023, then plummeted by 87.71% to $200000.0 in 2024, then skyrocketed by 2197.0% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Gains from Investment Securities are $4.6 million (Q4 2025), $330000.0 (Q3 2025), and $200000.0 (Q4 2024).